Investor Presentaiton
Manufacturing - Global Manufacturing System
(:)
Wanbang
(t)
Yao Pharma
Guilin Pharma
(Antimalarial drug)
Sino API Facility
Henlius
(+)
Gland
Avanc Pharma
(Special formulation)
Chongqing API Facility
Small Molecule API O Small Molecule Formulation
Biopharmaceutical
29
Henlius +24,000L
Commercial production capacity
Songjiang Facility Plant (1) received GMP
certification, increased commercial production
capacity from 24,000L to 48,000L
Songjiang Facility Plant (2) is under construction
with designed production capacity of 96,000L
Global Standard
Over 10 production lines for API and formulation of Yao
Pharma, Wanbang and Guilin Pharma received GMP
certification for the U.S., Europe and other markets
The production line of heparin sodium injection of
Wanbang passed the on-site review by the FDA and is
qualified to supply the U.S. market
Gland Pharma received GMP certifications from the
U.S., EU, Japan, Australia and other markets
Improved Efficiency: from API to formulation
Integration of manufacturing facilities to improve
efficiency, accelerating the construction of Xuzhou
and Chongqing comprehensive facilities and of
API facilities in Changsha, Xuzhou and Chongqing
( Sublicensed from MPP to manufacture oral COVID-
I 19 drugs from MSD and Pfizer with world-class
I manufacturing facilities and to commercialize in
agreed low and middle income countries
--View entire presentation